Table 1

Patients’ backgrounds

CharacteristicsNo. of patients (%)
Patients enrolled151
Median age55 (range, 20–86)
Menopausal status
Pre-62 (41.1)
Post-89 (58.9)
Tumor size
<2 cm6 (4.0)
2–5 cm97 (64.2)
>5 cm48 (31.8)
Number of nodes involved
054 (35.8)
1–337 (24.5)
≥460 (39.7)
Adjuvant therapya
CAF(CEF)−, 6 (4.0)
+, 38 (25.2)
CMF(CF)−, 5 (3.3)
+, 23 (15.2)
FU derivatives−, 12 (7.9)
+, 17 (11.3)
Tamoxifen−, 28 (18.5)
+, 72 (47.7)
  • a CAF(CEF), cyclophosphamide, Adriamycin or epirubicin and 5-FU; CMF(CF), cyclophosphamide, methotrexate, and 5-FU; −, negative for lymph node metastasis; +, positive for lymph node metastasis.